EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M)

Eine Phase-2-Studie zu Tipifarnib bei Kindern und jungen Erwachsenen mit Tumoren mit HRAS-genomischen Veränderungen: NCI-COG Pediatric MATCH-Studie (APEC1621M)

Christine A Pratilas iD, Marielle E Yohe iD, Paul M Williams, Joel M Reid iD, Jin Piao iD, Lauren Saguilig, David R Patton iD, Brent Coffey, Todd A Alonzo iD, Alexandria M Thompson iD, Nicole Arwood, Sinchita Roy-Chowdhuri iD und 11 weitere

The Oncologist · 05.11.2026 · 31 (12)

DOI: 10.1093/oncolo/oyag401 ↗

Auf einen Blick

In dieser Phase-2-Studie bei rezidivierten oder refraktären soliden Tumoren mit HRAS-Mutationen wurden keine objektiven Remissionen beobachtet. Ein Patient hatte nach Zyklus 2 eine stabile Erkrankung.

Fragestellung

Wirksamkeit, Progression-free Survival und Verträglichkeit von Tipifarnib bei Kindern mit soliden Tumoren und HRAS-Mutationen

Methode

Phase-2-Studie im NCI-COG Pediatric MATCH; Tipifarnib oral 2-mal täglich im intermittierenden Schema bis Progression oder nicht tolerabler Toxizität.

Ergebnisse

7 passende Patient:innen, 5 eingeschlossen. Diagnosen: Rhabdomyosarkom (n = 4) und Angiosarkom (n = 1). Keine objektiven Remissionen; 1 Patient mit stabiler Erkrankung bis Zyklus 4. UAW meist Grad 1/2.

Einschränkungen

Die Häufigkeit der identifizierten Mutationen und der eingeschlossenen Patient:innen war niedriger als erwartet; die Studie wurde vor vollständiger Rekrutierung beendet.

Schlussfolgerung der Autor:innen

Die Studie identifizierte erfolgreich pädiatrische Patient:innen mit HRAS-aktiven Tumoren. Für Tipifarnib wurde eine akzeptable Verträglichkeit und nur eine begrenzte Einzelwirkstoffaktivität beobachtet.

Kernaussagen

  • Keine objektiven Remissionen unter Tipifarnib
  • 1 Patient mit stabiler Erkrankung nach Zyklus 2
  • Verträglichkeit im intermittierenden Schema akzeptabel

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 09.10.2026. Verfasst von Christine A Pratilas und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Johns Hopkins University, Baltimore, MD 21287 United States. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms, Proto-Oncogene Proteins p21(ras), Quinolones. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCI, NCTN Operations Center.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

APEC1621 arm M, a subprotocol of the NCI-COG Pediatric MATCH clinical trial, is a phase 2 study evaluating tipifarnib, a farnesyl transferase inhibitor, in patients with relapsed or refractory solid tumors harboring HRAS mutations at codons G12, G13, Q61, or A146 (NCT04284774).

Methods

Patients identified by the MATCH screening protocol and enrolled to the arm M subprotocol received tipifarnib at 350 mg/m2/dose (maximum 600 mg/dose) orally twice daily on an intermittent dosing schedule (days 1-7 and 15-21, every 28 days) until disease progression or intolerable toxicity. The primary aim was to determine the objective response rate (ORR), and secondary objectives included estimating progression-free survival (PFS) and assessing the tolerability of tipifarnib on the intermittent dosing schedule in children.

Results

Seven patients matched to the tipifarnib subprotocol and five patients (71%) enrolled. Two matched patients were ineligible for treatment. Diagnoses for the enrolled patients were rhabdomyosarcoma (n = 4) and angiosarcoma (n = 1). HRAS mutations identified in those tumors included G13R (n = 2) and G12S, G12C, and Q61L (n = 1 each). Treatment was associated with grade 1/2 adverse events (AE) consistent with those expected from prior studies. Grade 3 or higher AEs on treatment were disease progression, dyspnea, and pleural effusion, not related to protocol therapy. One patient had stable disease (SD) at the end of cycle 2 and remained on protocol therapy for 4 cycles. There were no objective responses (OR).

Conclusions

This US cooperative group study was successful at identifying pediatric patients with tumors that harbored oncogenic mutations in HRAS. The frequency of the mutations identified and patients enrolled was lower than anticipated, and the study closed before accrual was complete. The adverse effect profile of tipifarnib in pediatric patients on the intermittent dosing schedule was acceptable. Limited single-agent efficacy of tipifarnib was observed in this biomarker-selected cohort of refractory pediatric tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsProto-Oncogene Proteins p21(ras)QuinolonesAdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultMutation

Stichwörter der Autor:innen

HRASfarnesyltransferase inhibitorpediatric MATCHrhabdomyosarcomatipifarnib

Substanzen

Antineoplastic AgentsHRAS protein, humanProto-Oncogene Proteins p21(ras)Quinolonestipifarnib

Autor:innen und Institutionen

  • Department of Oncology, Johns Hopkins University, Baltimore, MD 21287 United States.
  • Clinical Center, National Institutes of Health Clinical Center, Bethesda, MD 20892 United States.
  • Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States.
  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Comprehensive Cancer Center, Rochester, MN 55905, United States.
  • Department of Biostatistics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States.
  • Children's Oncology Group Statistical Center, Arcadia, CA 91006, United States.

ORCID-Profile: Christine A Pratilas, Marielle E Yohe, Joel M Reid, Jin Piao, David R Patton, Todd A Alonzo, Alexandria M Thompson, Sinchita Roy-Chowdhuri, Nilsa C Ramirez, Stacey L Berg, Elizabeth Fox, Brenda J Weigel, Douglas S Hawkins, Margaret M Mooney, Naoko Takebe, Katherine A Janeway, Nita L Seibel, Donald W Parsons

Förderung

  • NCI NIH HHS
  • NCI
  • NCTN Operations Center
  • COG Biospecimen Bank Grant
  • NCTN Statistics and Data Center Grant
  • NCI via Leidos
  • St. Baldrick's Foundation
  • Kura Oncology and the NCI

Zitieren

APA

Pratilas, C. A., Yohe, M. E., Williams, P. M., Reid, J. M., Piao, J., Saguilig, L., Patton, D. R., Coffey, B., Alonzo, T. A., Thompson, A. M., Arwood, N., Roy-Chowdhuri, S., Ramirez, N. C., Berg, S. L., Fox, E., Weigel, B. J., Hawkins, D. S., Mooney, M. M., Takebe, N., …, & Parsons, D. W. (2026). A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M). The Oncologist, 31(12). https://doi.org/10.1093/oncolo/oyag401

Vancouver

Pratilas CA, Yohe ME, Williams PM, Reid JM, Piao J, Saguilig L, et al. A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M). The Oncologist. 2026;31(12). doi:10.1093/oncolo/oyag401

BibTeX
@article{Pratilas2026,
  author = {Pratilas, Christine A and Yohe, Marielle E and Williams, Paul M and Reid, Joel M and Piao, Jin and Saguilig, Lauren and Patton, David R and Coffey, Brent and Alonzo, Todd A and Thompson, Alexandria M and Arwood, Nicole and Roy-Chowdhuri, Sinchita and Ramirez, Nilsa C and Berg, Stacey L and Fox, Elizabeth and Weigel, Brenda J and Hawkins, Douglas S and Mooney, Margaret M and Takebe, Naoko and Tricoli, James V and Janeway, Katherine A and Seibel, Nita L and Parsons, Donald W},
  title = {A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M)},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {12},
  doi = {10.1093/oncolo/oyag401}
}
Kostenlos starten →